Yale Cancer Center Researchers Awarded 2023-2024 Grants from the Breast Cancer Research Foundation
The Breast Cancer Research Foundation (BCRF) Scientific Advisory Board and its Board of Directors recently announced its $60.2 million commitment to fund breast cancer research in 2023-2024, supporting more than 250 scientists at leading academic and medical institutions, including eight grants at Yale Cancer Center and Smilow Cancer Hospital.
Screening Mammograms Carry Risks for Older Women, Study Finds
Although some guidelines recommend continuing screening for older women, this new study emphasizes the importance of assessing potential harms associated with testing, such as overdiagnosis, which, researchers say, can negatively affect quality of life.
Smilow Cancer Hospital Breast Surgeon Explains the Facts on Male Breast Cancer
Mehra Golshan, MD, MBA, clinical director of the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center explains the latest findings on male breast cancer and what patients need to know. Dr. Golshan is a breast cancer surgeon and a nationally recognized leader in breast cancer treatment and research. He also serves as Deputy Chief Medical Officer for Surgical Services at Smilow Cancer Hospital and is a professor of surgical oncology and the executive vice chair for operations in the department of surgery at the Yale School of Medicine. Dr. Golshan answered some commonly asked questions on male breast cancer.
New Study Shows Trastuzumab Deruxtecan Improves Survival for Patients with HER2-positive Metastatic Breast Cancer
A new phase III study has demonstrated the efficacy of trastuzumab deruxtecan (Enhertu) in patients with HER2-positive metastatic breast cancer whose cancers were resistant to previous treatment with trastuzumab emtansine. Both trastuzumab deruxtecan and trastuzumab emtansine are antibody-drug conjugates, a relatively new type of drug that delivers chemotherapy directly to the cancer cell, minimizing damage to normal tissues. The study was published in The Lancet on April 19, 2023.
‘This is About Saving Women’s Lives’: Find It Early Act Aims to Increase Breast Cancer Screenings
Congresswoman Rosa DeLauro announced the introduction of the Find It Early Act which, if passed, would require insurance companies to cover mammograms, breast ultrasounds, and MRIs to increase early cancer detection.
Smilow Cancer Hospital and Yale Police Team to Raise Breast Cancer Awareness
Members of Smilow Cancer Hospital and Yale Cancer Center spent time together on Friday, October 28 on the New Haven Green with members of the Yale Police Department – along with a special, pink-themed Yale Police SUV – to highlight Breast Cancer Awareness Month.
Fighting Breast and Ovarian Cancer With a Lupus Antibody
After discovering a specific lupus antibody that can penetrate cancer cells and, with a grant from Women's Health Research at Yale, showing it makes cancer cells vulnerable to standard treatments, Dr. Peter Glazer and his colleagues are moving a treatment to clinical trials.
Mutations Differ Across Younger and Older Breast Cancer Patients
Women younger than 40 years of age with advanced breast cancer often suffer from more aggressive disease and worse prognoses than their older counterparts. Knowing which types of genetic mutations these patients tend to have could inform treatment strategies and improve outcomes. In a new study, Yale Cancer Center researchers investigated the genomic alterations of patients with breast cancer, uncovering differences between younger and older patients.
Office Hours with… Maryam Lustberg
As director of the Breast Center at Smilow Cancer Hospital, Maryam Lustberg studies how to improve the quality of life of breast cancer patients. At home, she likes hanging out with her eight-year-old son. And at all times, she’s a big fan of coffee and sweets. We caught up with her for the latest edition of Office Hours, a Q&A series that introduces newcomers to the Yale faculty to the broader university community.Source: Yale News
Yale Scientists Reveal Molecular Pathway for Smarter Breast Cancer Drugs
New research at Yale has revealed major differences in aggressive types of breast cancer, and the potential for smarter treatments for patients. Triple-negative breast cancer, which has a low survival rate and a lack of helpful molecular biomarkers — specific proteins that signal the presence of disease — is among the most aggressive breast cancer subtypes.Source: Yale West Campus News